third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib): clinical trials recruiting now

Fewer than 3 recruiting trials found.

1

Recruiting trials

3

Conditions studied

0

US states with sites

1

Countries

Phase breakdown

Not applicable 1

Conditions being studied

Condition	Trials
Brain Metastasases	1
Lung cancer	1
NSCLC (Advanced Non-small Cell Lung Cancer)	1

Recruiting trials involving third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib)

AI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer Patients With Baseline Brain Metastases
NCT06604689 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

How many recruiting trials involve third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib)?

1 recruiting trial across 3 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.